APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica

Journal of Lipid Research

Volumn 46, Issue 12, 2005, Pages 2605-2613

  Ruiz Narváez, Edward A ^a   Yang, Yadong ^a   Nakanishi, Yukiko ^a   Kirchdorfer, Jill ^a   Campos, Hannia ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Apolipoprotein; Cardiovascular disease; Epidemiology; Genetics; Risk factors

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; LIPID; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COSTA RICA; FEMALE; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEART INFARCTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ALLELES; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS C; COSTA RICA; DIABETES MELLITUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC;

EID: 30844467076     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500040-JLR200     Document Type: Article

References (61)

1. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249: 790-793.
2. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
3. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
4. Ordovas, J. M., F. Civeira, J. Genest, Jr., S. Craig, A. H. Robbins, T. Meade, M. Pocovi, P. M. Frossard, U. Masharani, P. W. Wilson, et al. 1991. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 87: 75-86.
5. Surguchov, A. P., G. P. Page, L. Smith, W. Patsch, and E. Boerwinkle. 1996. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 16: 941-947.
6. Talmud, P. J., E. Hawe, S. Martin, M. Olivier, G. J. Miller, E. M. Rubin, L. A. Pennacchio, and S. E. Humphries. 2002. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11: 3039-3046.
7. Hubacek, J. A., Z. Skodova, V. Adamkova, V. Lanska, and R. Poledne. 2004. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin. Genet. 65: 126-130.
8. Li, W. W., M. M. Dammerman, J. D. Smith, S. Metzger, J. L. Breslow, and T. Leff. 1995. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J. Clin. Invest. 96: 2601-2605.
9. Olivieri, O., C. Stranieri, A. Bassi, B. Zaia, D. Girelli, F. Pizzolo, E. Trabetti, S. Cheng, M. A. Grow, P. F. Pignatti, et al. 2002. ApoC-III gene polymorphisms and risk of coronary artery disease. J. Lipid Res. 43: 1450-1457.
10. Olivieri, O., A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, and R. Corrocher. 2003. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J. Lipid Res. 44: 2374-2381.
11. Pennacchio, L. A., M. Olivier, J. A. Hubacek, R. M. Krauss, E. M. Rubin, and J. C. Cohen. 2002. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11: 3031-3038.
12. Kao, J. T., H. C. Wen, K. L. Chien, H. C. Hsu, and S. W. Lin. 2003. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum. Mol. Genet. 12: 2533-2539.
13. Ferns, G. A., J. Stocks, C. Ritchie, and D. J. Galton. 1985. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction. Lancet. 2: 300-303.
14. Russo, G. T., J. B. Meigs, L. A. Cupples, S. Demissie, J. D. Otvos, P. W. Wilson, C. Lahoz, D. Cucinotta, P. Couture, T. Mallory, et al. 2001. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis. 158: 173-181.
15. Wong, W. M., E. Hawe, L. K. Li, G. J. Miller, V. Nicaud, L. A. Pennacchio, S. E. Humphries, and P. J. Talmud. 2003. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ. Res. 92: 969-975.
16. Chhabra, S., R. Narang, R. Lakshmy, S. Vasisht, D. P. Agarwal, L. M. Srivastava, S. C. Manchanda, and N. Das. 2004. Apolipoprotein C3 SstI polymorphism in the risk assessment of CAD. Mol. Cell. Biochem. 259: 59-66.
17. Lai, C. Q., S. Demissie, L. A. Cupples, Y. Zhu, X. Adiconis, L. D. Parnell, D. Corella, and J. M. Ordovas. 2004. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J. Lipid Res. 45: 2096-2105.
18. Bi, N., S. K. Yan, G. P. Li, Z. N. Yin, and B. S. Chen. 2004. A single nucleotide polymorphism -1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol. Genet. Metab. 83: 280-286.
19. Szalai, C., M. Keszei, J. Duba, Z. Prohaszka, G. T. Kozma, A. Csaszar, S. Balogh, Z. Almassy, G. Fust, and A. Czinner. 2004. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis. 173: 109-114.
20. Lee, K. W., A. F. Ayyobi, J. J. Frohlich, and J. S. Hill. 2004. APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. Atherosclerosis. 176: 165-172.
21. Talmud, P. J., S. Martin, M. R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, S. E. Humphries, and M. Syvanne. 2004. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J. Lipid Res. 45: 750-756.
22. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 2003. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 26 (Suppl.): 5-20.
23. Rose, G. A., H. Blackburn, R. F. Gillum, and R. J. Prineas. 1982. Cardiovascular Survey Methods. World Health Organization, Geneva.
24. Groenendijk, M., R. M. Cantor, T. W. de Bruin, and G. M. Dallinga-Thie. 2001. The apoAI-CIII-AIV gene cluster. Atherosclerosis. 157: 1-11.
25. Kabagambe, E. K., A. Baylin, D. A. Allan, X. Siles, D. Spiegelman, and H. Campos. 2001. Application of the method of triads to evaluate the performance of food frequency questionnaires and biomarkers as indicators of long-term dietary intake. Am. J. Epidemiol. 154: 1126-1135.
26. Baylin, A., E. K. Kabagambe, X. Siles, and H. Campos. 2002. Adipose tissue biomarkers of fatty acid intake. Am. J. Clin. Nutr. 76: 750-757.
27. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
28. Lewontin, R. C. 1964. The interaction of selection and linkage. II. Optimum models. Genetics. 50: 757-782.
29. Zaykin, D. V., P. H. Westfall, S. S. Young, M. A. Karnoub, M. J. Wagner, and M. G. Ehm. 2002. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum. Hered. 53: 79-91.
30. Stram, D. O., C. Leigh Pearce, P. Bretsky, M. Freedman, J. N. Hirschhorn, D. Altshuler, L. N. Kolonel, B. E. Henderson, and D. C. Thomas. 2003. Modeling and E-M estimation of haplotypespecific relative risks from genotype data for a case-control study of unrelated individuals. Hum. Hered. 55: 179-190.
31. Baroukh, N., E. Bauge, J. Akiyama, J. Chang, V. Afzal, J. C. Fruchart, E. M. Rubin, J. Fruchart-Najib, and L. A. Pennacchio. 2004. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 24: 1297-1302.
32. Chen, M., J. L. Breslow, W. Li, and T. Leff. 1994. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res. 35: 1918-1924.
33. Venkatesan, S., H. Imrie, S. Read, and D. Halliday. 1995. Apo C subclasses from non-insulin-dependent diabetic patients-a quantitative comparison with control subjects. Biochem. Soc. Trans. 23 (Suppl.): 278.
34. Dammerman, M., L. A. Sandkuijl, J. L. Halaas, W. Chung, and J. L. Breslow. 1993. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA. 90: 4562-4566.
35. Shoulders, C. C., T. T. Grantham, J. D. North, A. Gaspardone, F. Tomai, A. de Fazio, F. Versaci, P. A. Gioffre, and N. J. Cox. 1996. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum. Genet. 98: 557-566.
36. Dallinga-Thie, G. M., M. Groenendijk, R. N. Blom, T. W. De Bruin, and E. De Kant. 2001. Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin. J. Lipid Res. 42: 1450-1456.
37. Nowak, M., A. Helleboid-Chapman, H. Jakel, G. Martin, D. Duran-Sandoval, B. Staels, E. M. Rubin, L. A. Pennacchio, M. R. Taskinen, J. Fruchart-Najib, et al. 2005. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol. Cell. Biol. 25: 1537-1548.
38. Raspe, E., H. Duez, P. Gervois, C. Fievet, J. C. Fruchart, S. Besnard, J. Mariani, A. Tedgui, and B. Staels. 2001. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J. Biol. Chem. 276: 2865-2871.
39. Genoux, A., H. Dehondt, A. Helleboid-Chapman, C. Duhem, D. W. Hum, G. Martin, L. A. Pennacchio, B. Staels, J. Fruchart-Najib, and J. C. Fruchart. 2005.Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler. Thromb. Vasc. Biol. 25: 1186-1192.
40. Prieur, X., H. Coste, and J. C. Rodriguez. 2003. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J. Biol. Chem. 278: 25468-25480.
41. Hertz, R., J. Bishara-Shieban, and J. Bar-Tana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J. Biol. Chem. 270: 13470-13475.
42. Coste, H., and J. C. Rodriguez. 2002. Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter. J. Biol. Chem. 277: 27120-27129.
43. Pennacchio, L. A., and E. M. Rubin. 2003. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler. Thromb. Vasc. Biol. 23: 529-534.
44. Beutler, B., and T. Brown. 1993. Polymorphism of the mouse TNFalpha locus: sequence studies of the 3′-untranslated region and first intron. Gene. 129: 279-283.
45. Zaidi, S. H., R. Denman, and J. S. Malter. 1994. Multiple proteins interact at a unique cis-element in the 3′-untranslated region of amyloid precursor protein mRNA. J. Biol. Chem. 269: 24000-24006.
46. Sachs, A. B. 1993. Messenger RNA degradation in eukaryotes. Cell. 74: 413-421.
47. Marz, W., G. Schenk, and W. Gross. 1987. Apolipoproteins C-II and C-III in serum quantified by zone immunoelectrophoresis. Clin. Chem. 33: 664-669.
48. Sakurabayashi, I., Y. Saito, T. Kita, Y. Matsuzawa, and Y. Goto. 2001. Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin. Chim. Acta. 312: 87-95.
49. Noma, A., Y. Hata, and Y. Goto. 1991. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences. Clin. Chim. Acta. 199: 147-157.
50. O'Brien, P. J., W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad. 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51: 351-359.
51. Schaap, F. G., P. C. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein- triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279: 27941-27947.
52. Martin, S., V. Nicaud, S. E. Humphries, and P. J. Talmud. 2003. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim. Biophys. Acta. 1637: 217-225.
53. Olivier, M., X. Wang, R. Cole, B. Gau, J. Kim, E. M. Rubin, and L. A. Pennacchio. 2004. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics. 83: 912-923.
54. Lai, C. Q., E. S. Tai, C. E. Tan, J. Cutter, S. K. Chew, Y. P. Zhu, X. Adiconis, and J. M. Ordovas. 2003. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J. Lipid Res. 44: 2365-2373.
55. Neale, B. M., and P. C. Sham. 2004. The future of association studies: gene-based analysis and replication. Am. J. Hum. Genet. 75: 353-362.
56. Crawford, D. C., C. S. Carlson, M. J. Rieder, D. P. Carrington, Q. Yi, J. D. Smith, M. A. Eberle, L. Kruglyak, and D. A. Nickerson. 2004. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am. J. Hum. Genet. 74: 610-622.
57. Efron, B., and R. Tibshirani. 2002. Empirical bayes methods and false discovery rates for microarrays. Genet. Epidemiol. 23: 70-86.
58. Sabatti, C., S. Service, and N. Freimer. 2003. False discovery rate in linkage and association genome screens for complex disorders. Genetics. 164: 829-833.
59. Wacholder, S., S. Chanock, M. Garcia-Closas, L. El Ghormli, and N. Rothman. 2004. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 96: 434-442.
60. Olin-Lewis, K., R. M. Krauss, M. La Belle, P. J. Blanche, P. H. Barrett, T. N. Wight, and A. Chait. 2002. ApoC-III content of apoBcontaining lipoproteins is associated with binding to the vascular proteoglycan biglycan. J. Lipid Res. 43: 1969-1977.
61. Juntti-Berggren, L., E. Refai, I. Appelskog, M. Andersson, G. Imreh, N. Dekki, S. Uhles, L. Yu, W. J. Griffiths, S. Zaitsev, et al. 2004. Apolipoprotein CIII promotes Ca2+ -dependent beta cell death in type 1 diabetes. Proc. Natl. Acad. Sci. USA. 101: 10090-10094.